BiotechTube
Home/Pipeline/JSKN022

JSKN022

Not specified

Phase 1Active

Key Facts

Indication
Not specified
Phase
Phase 1
Status
Active
Company
AlphaMab Oncology

About AlphaMab Oncology

AlphaMab Oncology develops innovative bispecific antibodies and ADCs for cancer treatment using proprietary glycan-specific conjugation and CRIB platforms.

View full company profile

Therapeutic Areas

Oncology

Other Not specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved
Collaborative Program with FerringPharmaBiomeResearch